Allogene director granted 144,400 stock options at $2

Allogene Therapeutics director Stephen Mayo received a new stock option grant covering 144,400 shares of common stock.

Rhea-AI Filing Summary

Allogene Therapeutics director Stephen Mayo received a new stock option grant covering 144,400 shares of common stock. The options have an exercise price of $2.00 per share and vest in 12 equal monthly installments. Following this award, he holds options for 144,400 shares, expiring on June 18, 2036.

Insider Trade Summary

Grant/Award: 144,400 shares

Grant/Award 1 txn

Insider Mayo Stephen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	144,400	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 144,400 contracts (Direct)

Footnotes (1)

1. F1. Vesting in 12 equal monthly installments.

Key Figures

Option grant size: 144,400 shares Exercise price: $2.00 per share Shares after transaction: 144,400 options +3 more

6 metrics

Option grant size 144,400 shares Stock Option (Right to buy) awarded to Stephen Mayo

Exercise price $2.00 per share Conversion or exercise price of stock options

Shares after transaction 144,400 options Total derivative shares following transaction

Expiration date June 18, 2036 Option expiration date

Vesting schedule 12 equal monthly installments Footnote describing option vesting

Transaction date June 18, 2026 Date of option grant

Key Terms

Stock Option (Right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 2.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Vesting in 12 equal monthly installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-18T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Allogene Therapeutics (ALLO) director Stephen Mayo report on this Form 4?

Stephen Mayo reported receiving a stock option grant for 144,400 shares of Allogene Therapeutics common stock. These options are a form of equity compensation and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Stephen Mayo’s new Allogene stock options?

The new options have an exercise price of $2.00 per share. This means Mayo can purchase Allogene common stock at $2.00 per share when he exercises the options, subject to vesting and the option’s expiration date.

How do Stephen Mayo’s Allogene stock options vest according to the filing?

The filing notes the options vest in 12 equal monthly installments. This schedule gradually makes portions of the 144,400-share award exercisable each month over one year, tying the benefit to continued service during that period.

When do Stephen Mayo’s newly granted Allogene stock options expire?

The options expire on June 18, 2036, giving a long-term exercise window. After that date, any unexercised portion of the 144,400-share grant will lapse and can no longer be used to purchase Allogene common stock.

How many Allogene shares are covered by Stephen Mayo’s option holdings after this grant?

After this grant, Mayo holds options for 144,400 shares of Allogene common stock. This figure reflects the total derivative position reported in the Form 4 for this award, all at a $2.00 exercise price per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mayo Stephen

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$2	06/18/2026		A		144,400		(1)	06/18/2036	Common Stock	144,400	$0	144,400	D

Explanation of Responses:

1. Vesting in 12 equal monthly installments.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)